ArticleAmerican journal of translational research2024
Comprehensive analysis of the transcription factor CREB3L4/RASEF signaling axis in lung adenocarcinoma: implications for pathogenesis and therapeutic strategies.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to elucidate the role of cAMP responsive element binding protein 3 like 4 (CREB3L4) in the pathogenesis of lung adenocarcinoma (LUAD) and to provide new insights and approaches for its effective treatment. An analysis was conducted on the expression and prognostic implications of CREB3L4 in LUAD.
methodsPotential downstream target genes regulated by CREB3L4 were identified through chromatin immunoprecipitation assay sequencing and mRNA sequencing analyses, and the regulatory relationship, mechanism, and prognostic significance of the identified target gene in LUAD were subsequently confirmed. Moreover, immune microenvironment analysis, the identification of immunotherapy targets, and chemotherapy drug sensitivity analyses were performed for LUAD with different levels of CREB3L4 expression.
resultsCREB3L4 is upregulated in LUAD and is significantly associated with tumor staging and poor prognosis, influencing cell proliferation and migration. Comprehensive analysis through chromatin immunoprecipitation assay sequencing and mRNA sequencing highlighted RAS and EF-hand domain containing (RASEF) as a potential target gene under the regulation of CREB3L4, which was found to be overexpressed in LUAD and linked to tumor staging, as well as cell proliferation and migration. Notably, the knockdown of CREB3L4 markedly reduced RASEF promoter-driven luciferase activity. The aberrant expression of CREB3L4 in LUAD was intricately related to the complex tumor microenvironment and immune therapy targets, including PD-L1, CTLA-4, CD28, CD80, and demonstrated increased sensitivity to chemotherapy drugs such as osimertinib, gefitinib, and afatinib.
conclusionsThese findings provide preliminary evidence for the involvement of the CREB3L4/RASEF signaling pathway in LUAD pathogenesis and suggest its potential as a novel biomarker for accurate diagnosis and targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.